Computational Biology Market By Application (Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials, Human Body Simulation Software), By Services (In-house, Contract), By End Use (Academics & Research, Commercial): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global computational biology market was valued at $5,493.2 million in 2021, and is projected to reach $31,477.1 million by 2031, registering a CAGR of 19.5% from 2022 to 2031.
Computational biology is the inter-disciplinary applied science, which utilizes concepts of basic biology through the use of mathematical, theoretical, and computer simulation models to study biological systems, structures, and processes of life.. It entails the use of computational methods (e.g., algorithms) for the representation and simulation of biological systems as well as for the interpretation of experimental data, often on a very large scale.
The sequence and structural similarities of an unknown and a known protein as well as the proteins’ interactions with other molecules are used to make functional predictions. As such analyses can be lengthy, the demand for computational biology has increased rapidly., Therefore, these analyses guide the process of building 3D models of the target protein structure, which are then refined, ranked, and compared with one another to select the final predictions.. Biochemical, regulatory, and genetic pathways are highly branched and interleaved, as well as dynamic, necessitating the use of advanced computational methods to model and analyze them.
The COVID-19 pandemic has had an impact on the computational biology market. To curb the spread of COVID-19, governments around the world implemented harsh restrictions such as border locks, lockdowns, and tight social distancing measures. These measures had a significant impact on the global economy, affecting a variety of industries. Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline.
Furthermore, the outbreak of COVID-19 led to high mortality, high contagion rate, and a lack of clinically approved drugs and vaccines. To find safe and effective therapeutic options to treat this infectious disease, computational biology plays an extremely relevant role to better understand the virus pathogenic mechanism as well as to propose novel therapeutic strategies. Accordingly, due to progress in computer science, in silico methodologies in medicinal chemistry, pharmacology, biology, genetics, and virology cover relevant tasks in modern research in these fields. Furthermore, due to the current global health warning, such computational techniques could speed up research to provide innovative and targeted approaches to fight the coronavirus emergency. Hence, computational biology will help the medical science field irreversibly to find a cure and boost the growth of the pharma market.
The growth of the global computational biology market is majorly driven by rise in demand for tools of computational biology in various fields such as genomics, epi-genomics, proteomics, and meta-genomics for better understanding of protein structure and interactions.. In addition, factors fueling the market growth include rise in R&D activities for drug discovery, surge in demand for predictive models, usage in population-based sequencing projects such as human genome project, and government funding.
The application of sophisticated algorithms and statistical models in computational biology to analyze biological data enables researchers to gather critical insights, which can be utilized for discovery of new drugs. Moreover, application of machine learning and artificial intelligence allowed researchers to develop a better understanding of biological systems, discovering new drugs, designing new proteins to cure diseases, and help in understanding genetic code to predict diseases. Several start-ups in computational biology provide software platform that contributes to the pharmaceutical development process. This is expected to contribute to revenue growth of the market.
Moreover, increase in demand from the contract research organization for computational biology drives the growth of the market. Contract research organization service providers work with clients to develop a customized plan as per the requirements. For instance, the Bioinformatics CRO, Inc. is a contract research organization that offers bioinformatics services to biotechnology companies worldwide.
The computational biology software/tools help in building custom analytical pipelines to generate more critical insights from data also it can be used to further analyze gene expression data from bulk and single-cell RNA-sequence, and perform network analysis such as Weighted Gene Co-expression Network Analysis (WGCNA). Various sectors such as the pharmaceutical, biotechnology, and medical device use computational biology for developing their products. Thus, rapid development of these sectors notably contributes toward the growth of the global computational biology market.
However, complications such as allergic reactions that cannot be detected by computational biology and other post-surgery complications, unfavorable government scenario, high initial cost & maintenance costs of the instruments, lack of standardization, and shortage of skilled workforce act as the key deterrent factors of the global market.
The global computational biology market is segmented into application, service, and end use, and region. By application, the market is segregated into cellular & biological simulation, drug discovery & disease modeling, pre-clinical drug development, clinical trials, and human body simulation software.
The cellular & biological simulation is sub-segmented into computer, genomics, computational proteomics, pharmacogenomics, and others. The drug discovery & disease modeling segregated into target identification, target validation, lead discovery, and lead optimization. The pre-clinical drug development segmented into pharmacokinetics and pharmacodynamics. The clinical trials are subcategorized into phase I, phase II, and phase III.
On the basis of services, the segment is divided into in-house services and contract. On the basis of end use the segment is divided into academics & research and commercials. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies that operate in the computational biology market are Altaris Capital Partner, Compugen Ltd., Certara, Genedata AG, Dassault Systems, DNAnexus, Nimbus Discovery, Instem, Rosa & Co. Ltd, and Simulation Plus.
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis along with the current computational biology market trends from 2022 to 2031 to identify the prevailing opportunities along with the strategic assessment.
The computational biology market forecast is studied from 2022 to 2031.
The market size and estimations are based on a comprehensive analysis of key developments in the computational biology industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the computational biology market.
Key Market Segments
By Application
Cellular Biological Simulation
Drug Discovery Disease Modelling
Preclinical Drug Development
Clinical Trials
Human Body Simulation Software
By Services
Contract
In-house
By End Use
Academics Research
Commercial
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Chemical Computing Group Inc.
Compugen Ltd.
Simulation Plus Inc.
Genedata AG
Certara
Insilico Biotechnology AG
Accelrys
Rhenovia Pharma SAS
Entelos
Nimbus Discovery LLC
Rhenovia Pharma SAS & Leadscope Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Cellular & Biological Simulation
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Drug Discovery & Disease Modelling
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Preclinical Drug Development
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Clinical Trials
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 Human Body Simulation Software
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
- CHAPTER 5: COMPUTATIONAL BIOLOGY MARKET, BY SERVICES
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 In-house
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Contract
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- CHAPTER 6: COMPUTATIONAL BIOLOGY MARKET, BY END USE
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Academics & Research
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Commercial
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- CHAPTER 7: COMPUTATIONAL BIOLOGY MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Application
- 7.2.3 North America Market size and forecast, by Services
- 7.2.4 North America Market size and forecast, by End Use
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Application
- 7.2.5.1.2 Market size and forecast, by Services
- 7.2.5.1.3 Market size and forecast, by End Use
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Application
- 7.2.5.2.2 Market size and forecast, by Services
- 7.2.5.2.3 Market size and forecast, by End Use
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Application
- 7.2.5.3.2 Market size and forecast, by Services
- 7.2.5.3.3 Market size and forecast, by End Use
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Application
- 7.3.3 Europe Market size and forecast, by Services
- 7.3.4 Europe Market size and forecast, by End Use
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Application
- 7.3.5.1.2 Market size and forecast, by Services
- 7.3.5.1.3 Market size and forecast, by End Use
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Application
- 7.3.5.2.2 Market size and forecast, by Services
- 7.3.5.2.3 Market size and forecast, by End Use
- 7.3.5.3 United Kingdom
- 7.3.5.3.1 Market size and forecast, by Application
- 7.3.5.3.2 Market size and forecast, by Services
- 7.3.5.3.3 Market size and forecast, by End Use
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Application
- 7.3.5.4.2 Market size and forecast, by Services
- 7.3.5.4.3 Market size and forecast, by End Use
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Application
- 7.3.5.5.2 Market size and forecast, by Services
- 7.3.5.5.3 Market size and forecast, by End Use
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Application
- 7.3.5.6.2 Market size and forecast, by Services
- 7.3.5.6.3 Market size and forecast, by End Use
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Application
- 7.4.3 Asia-Pacific Market size and forecast, by Services
- 7.4.4 Asia-Pacific Market size and forecast, by End Use
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Application
- 7.4.5.1.2 Market size and forecast, by Services
- 7.4.5.1.3 Market size and forecast, by End Use
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Application
- 7.4.5.2.2 Market size and forecast, by Services
- 7.4.5.2.3 Market size and forecast, by End Use
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Application
- 7.4.5.3.2 Market size and forecast, by Services
- 7.4.5.3.3 Market size and forecast, by End Use
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Application
- 7.4.5.4.2 Market size and forecast, by Services
- 7.4.5.4.3 Market size and forecast, by End Use
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Application
- 7.4.5.5.2 Market size and forecast, by Services
- 7.4.5.5.3 Market size and forecast, by End Use
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Application
- 7.4.5.6.2 Market size and forecast, by Services
- 7.4.5.6.3 Market size and forecast, by End Use
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Application
- 7.5.3 LAMEA Market size and forecast, by Services
- 7.5.4 LAMEA Market size and forecast, by End Use
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Application
- 7.5.5.1.2 Market size and forecast, by Services
- 7.5.5.1.3 Market size and forecast, by End Use
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Application
- 7.5.5.2.2 Market size and forecast, by Services
- 7.5.5.2.3 Market size and forecast, by End Use
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Application
- 7.5.5.3.2 Market size and forecast, by Services
- 7.5.5.3.3 Market size and forecast, by End Use
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Application
- 7.5.5.4.2 Market size and forecast, by Services
- 7.5.5.4.3 Market size and forecast, by End Use
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Chemical Computing Group Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Compugen Ltd.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Simulation Plus Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Genedata AG
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Certara
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Insilico Biotechnology AG
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Accelrys
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Rhenovia Pharma SAS
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Entelos
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Nimbus Discovery LLC
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Rhenovia Pharma SAS & Leadscope Inc.
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 2. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR CELLULAR & BIOLOGICAL SIMULATION, BY REGION , 2021-2031,($MILLION)
- TABLE 3. COMPUTATIONAL BIOLOGY MARKET FOR CELLULAR & BIOLOGICAL SIMULATION BY COUNTRY, 2021-2031,($MILLION)
- TABLE 4. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR DRUG DISCOVERY & DISEASE MODELLING, BY REGION , 2021-2031,($MILLION)
- TABLE 5. COMPUTATIONAL BIOLOGY MARKET FOR DRUG DISCOVERY & DISEASE MODELLING BY COUNTRY, 2021-2031,($MILLION)
- TABLE 6. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR PRECLINICAL DRUG DEVELOPMENT, BY REGION , 2021-2031,($MILLION)
- TABLE 7. COMPUTATIONAL BIOLOGY MARKET FOR PRECLINICAL DRUG DEVELOPMENT BY COUNTRY, 2021-2031,($MILLION)
- TABLE 8. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR CLINICAL TRIALS, BY REGION , 2021-2031,($MILLION)
- TABLE 9. COMPUTATIONAL BIOLOGY MARKET FOR CLINICAL TRIALS BY COUNTRY, 2021-2031,($MILLION)
- TABLE 10. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR HUMAN BODY SIMULATION SOFTWARE, BY REGION , 2021-2031,($MILLION)
- TABLE 11. COMPUTATIONAL BIOLOGY MARKET FOR HUMAN BODY SIMULATION SOFTWARE BY COUNTRY, 2021-2031,($MILLION)
- TABLE 12. GLOBAL COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 13. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR IN-HOUSE, BY REGION , 2021-2031,($MILLION)
- TABLE 14. COMPUTATIONAL BIOLOGY MARKET FOR IN-HOUSE BY COUNTRY, 2021-2031,($MILLION)
- TABLE 15. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR CONTRACT, BY REGION , 2021-2031,($MILLION)
- TABLE 16. COMPUTATIONAL BIOLOGY MARKET FOR CONTRACT BY COUNTRY, 2021-2031,($MILLION)
- TABLE 17. GLOBAL COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 18. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR ACADEMICS & RESEARCH, BY REGION , 2021-2031,($MILLION)
- TABLE 19. COMPUTATIONAL BIOLOGY MARKET FOR ACADEMICS & RESEARCH BY COUNTRY, 2021-2031,($MILLION)
- TABLE 20. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR COMMERCIAL, BY REGION , 2021-2031,($MILLION)
- TABLE 21. COMPUTATIONAL BIOLOGY MARKET FOR COMMERCIAL BY COUNTRY, 2021-2031,($MILLION)
- TABLE 22. COMPUTATIONAL BIOLOGY MARKET, BY REGION, 2021-2031,($MILLION)
- TABLE 23. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 24. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 25. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 26. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET, BY COUNTRY, 2021-2031,($MILLION)
- TABLE 27. U.S. COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 28. U.S. COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 29. U.S. COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 30. CANADA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 31. CANADA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 32. CANADA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 33. MEXICO COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 34. MEXICO COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 35. MEXICO COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 36. EUROPE COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 37. EUROPE COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 38. EUROPE COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 39. EUROPE COMPUTATIONAL BIOLOGY MARKET, BY COUNTRY, 2021-2031,($MILLION)
- TABLE 40. GERMANY COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 41. GERMANY COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 42. GERMANY COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 43. FRANCE COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 44. FRANCE COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 45. FRANCE COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 46. UNITED KINGDOM COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 47. UNITED KINGDOM COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 48. UNITED KINGDOM COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 49. ITALY COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 50. ITALY COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 51. ITALY COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 52. SPAIN COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 53. SPAIN COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 54. SPAIN COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 55. REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 56. REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 57. REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 58. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 59. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 60. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 61. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY COUNTRY, 2021-2031,($MILLION)
- TABLE 62. JAPAN COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 63. JAPAN COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 64. JAPAN COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 65. CHINA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 66. CHINA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 67. CHINA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 68. AUSTRALIA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 69. AUSTRALIA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 70. AUSTRALIA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 71. INDIA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 72. INDIA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 73. INDIA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 74. SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 75. SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 76. SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 77. REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 78. REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 79. REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 80. LAMEA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 81. LAMEA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 82. LAMEA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 83. LAMEA COMPUTATIONAL BIOLOGY MARKET, BY COUNTRY, 2021-2031,($MILLION)
- TABLE 84. BRAZIL COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 85. BRAZIL COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 86. BRAZIL COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 87. SAUDI ARABIA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 88. SAUDI ARABIA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 89. SAUDI ARABIA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 90. SOUTH AFRICA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 91. SOUTH AFRICA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 92. SOUTH AFRICA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 93. REST OF LAMEA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
- TABLE 94. REST OF LAMEA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
- TABLE 95. REST OF LAMEA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
- TABLE 96.CHEMICAL COMPUTING GROUP INC.: COMPANY SNAPSHOT
- TABLE 97.CHEMICAL COMPUTING GROUP INC.: OPERATING SEGMENTS
- TABLE 98.CHEMICAL COMPUTING GROUP INC.: PRODUCT PORTFOLIO
- TABLE 99.CHEMICAL COMPUTING GROUP INC.: NET SALES,
- TABLE 100.CHEMICAL COMPUTING GROUP INC.: KEY STRATERGIES
- TABLE 101.COMPUGEN LTD.: COMPANY SNAPSHOT
- TABLE 102.COMPUGEN LTD.: OPERATING SEGMENTS
- TABLE 103.COMPUGEN LTD.: PRODUCT PORTFOLIO
- TABLE 104.COMPUGEN LTD.: NET SALES,
- TABLE 105.COMPUGEN LTD.: KEY STRATERGIES
- TABLE 106.SIMULATION PLUS INC.: COMPANY SNAPSHOT
- TABLE 107.SIMULATION PLUS INC.: OPERATING SEGMENTS
- TABLE 108.SIMULATION PLUS INC.: PRODUCT PORTFOLIO
- TABLE 109.SIMULATION PLUS INC.: NET SALES,
- TABLE 110.SIMULATION PLUS INC.: KEY STRATERGIES
- TABLE 111.GENEDATA AG: COMPANY SNAPSHOT
- TABLE 112.GENEDATA AG: OPERATING SEGMENTS
- TABLE 113.GENEDATA AG: PRODUCT PORTFOLIO
- TABLE 114.GENEDATA AG: NET SALES,
- TABLE 115.GENEDATA AG: KEY STRATERGIES
- TABLE 116.CERTARA: COMPANY SNAPSHOT
- TABLE 117.CERTARA: OPERATING SEGMENTS
- TABLE 118.CERTARA: PRODUCT PORTFOLIO
- TABLE 119.CERTARA: NET SALES,
- TABLE 120.CERTARA: KEY STRATERGIES
- TABLE 121.INSILICO BIOTECHNOLOGY AG: COMPANY SNAPSHOT
- TABLE 122.INSILICO BIOTECHNOLOGY AG: OPERATING SEGMENTS
- TABLE 123.INSILICO BIOTECHNOLOGY AG: PRODUCT PORTFOLIO
- TABLE 124.INSILICO BIOTECHNOLOGY AG: NET SALES,
- TABLE 125.INSILICO BIOTECHNOLOGY AG: KEY STRATERGIES
- TABLE 126.ACCELRYS: COMPANY SNAPSHOT
- TABLE 127.ACCELRYS: OPERATING SEGMENTS
- TABLE 128.ACCELRYS: PRODUCT PORTFOLIO
- TABLE 129.ACCELRYS: NET SALES,
- TABLE 130.ACCELRYS: KEY STRATERGIES
- TABLE 131.RHENOVIA PHARMA SAS: COMPANY SNAPSHOT
- TABLE 132.RHENOVIA PHARMA SAS: OPERATING SEGMENTS
- TABLE 133.RHENOVIA PHARMA SAS: PRODUCT PORTFOLIO
- TABLE 134.RHENOVIA PHARMA SAS: NET SALES,
- TABLE 135.RHENOVIA PHARMA SAS: KEY STRATERGIES
- TABLE 136.ENTELOS: COMPANY SNAPSHOT
- TABLE 137.ENTELOS: OPERATING SEGMENTS
- TABLE 138.ENTELOS: PRODUCT PORTFOLIO
- TABLE 139.ENTELOS: NET SALES,
- TABLE 140.ENTELOS: KEY STRATERGIES
- TABLE 141.NIMBUS DISCOVERY LLC: COMPANY SNAPSHOT
- TABLE 142.NIMBUS DISCOVERY LLC: OPERATING SEGMENTS
- TABLE 143.NIMBUS DISCOVERY LLC: PRODUCT PORTFOLIO
- TABLE 144.NIMBUS DISCOVERY LLC: NET SALES,
- TABLE 145.NIMBUS DISCOVERY LLC: KEY STRATERGIES
- TABLE 146.RHENOVIA PHARMA SAS & LEADSCOPE INC.: COMPANY SNAPSHOT
- TABLE 147.RHENOVIA PHARMA SAS & LEADSCOPE INC.: OPERATING SEGMENTS
- TABLE 148.RHENOVIA PHARMA SAS & LEADSCOPE INC.: PRODUCT PORTFOLIO
- TABLE 149.RHENOVIA PHARMA SAS & LEADSCOPE INC.: NET SALES,
- TABLE 150.RHENOVIA PHARMA SAS & LEADSCOPE INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.COMPUTATIONAL BIOLOGY MARKET SEGMENTATION
- FIGURE 2.COMPUTATIONAL BIOLOGY MARKET,2021-2031
- FIGURE 3.COMPUTATIONAL BIOLOGY MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.COMPUTATIONAL BIOLOGY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.COMPUTATIONAL BIOLOGY MARKET,BY APPLICATION,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CELLULAR & BIOLOGICAL SIMULATION COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DRUG DISCOVERY & DISEASE MODELLING COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF PRECLINICAL DRUG DEVELOPMENT COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIALS COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HUMAN BODY SIMULATION SOFTWARE COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
- FIGURE 18.COMPUTATIONAL BIOLOGY MARKET,BY SERVICES,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF IN-HOUSE COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CONTRACT COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
- FIGURE 21.COMPUTATIONAL BIOLOGY MARKET,BY END USE,2021(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ACADEMICS & RESEARCH COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF COMMERCIAL COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
- FIGURE 24.COMPUTATIONAL BIOLOGY MARKET BY REGION,2021
- FIGURE 25.U.S. COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 26.CANADA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 27.MEXICO COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 28.GERMANY COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 29.FRANCE COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 30.UNITED KINGDOM COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 31.ITALY COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 32.SPAIN COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 33.REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 34.JAPAN COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 35.CHINA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 36.AUSTRALIA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 37.INDIA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 38.SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 39.REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 40.BRAZIL COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 41.SAUDI ARABIA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 42.SOUTH AFRICA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 43.REST OF LAMEA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
- FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 48.COMPETITIVE DASHBOARD
- FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 50.CHEMICAL COMPUTING GROUP INC..: NET SALES ,($MILLION)
- FIGURE 51.COMPUGEN LTD..: NET SALES ,($MILLION)
- FIGURE 52.SIMULATION PLUS INC..: NET SALES ,($MILLION)
- FIGURE 53.GENEDATA AG.: NET SALES ,($MILLION)
- FIGURE 54.CERTARA.: NET SALES ,($MILLION)
- FIGURE 55.INSILICO BIOTECHNOLOGY AG.: NET SALES ,($MILLION)
- FIGURE 56.ACCELRYS.: NET SALES ,($MILLION)
- FIGURE 57.RHENOVIA PHARMA SAS.: NET SALES ,($MILLION)
- FIGURE 58.ENTELOS.: NET SALES ,($MILLION)
- FIGURE 59.NIMBUS DISCOVERY LLC.: NET SALES ,($MILLION)
- FIGURE 60.RHENOVIA PHARMA SAS & LEADSCOPE INC..: NET SALES ,($MILLION)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook